ViruCure is biotech company developing an oncolytic-virus-based technology platform for the treatment of cancer. ViruCure has developed a product using viruses that recognize, target, and destroy cancer cells (Oncolytic virus).
The product is based on breakthrough research that has provided evidential proof of this concept in human terminal Glioblastoma patients (GBM). The virus extended the life of 33% of the patients, caused tumor shrinkage, and in some patients resulted in complete remission of the cancer. These results are dramatic in light of the fact that there has been no effective treatment for these types of tumors to date.